Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm to Report Third Quarter 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021 , 4:30 p.m. ET CELEBRATION, Fla. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION, Fla. , Oct. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc.  (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)
CELEBRATION, Fla. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc.  (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS ® and serdexmethylphenidate (SDX), the company’s proprietary
Toggle Summary KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
Trading to commence effective with the open of business on October 19, 2021 CELEBRATION, Fla. , Oct. 19, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc.  (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its shares of
Toggle Summary KemPharm to Present at the Benzinga Healthcare Small Cap Conference
CELEBRATION, Fla. , Sept. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will present
Toggle Summary KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
CELEBRATION, Fla. , Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will present
Toggle Summary KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
CELEBRATION, Fla. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will present
Toggle Summary KemPharm Appoints Tamara A. Seymour to Board of Directors
CELEBRATION, Fla. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the
Toggle Summary KemPharm Reports Second Quarter 2021 Financial Results
Corporate and Regulatory Highlights U.S. Commercial Launch of AZSTARYS™ Initiated on July 21, 2021 Serdexmethylphenidate (SDX) Classified as a Schedule IV Controlled Substance by the DEA Announced Orange Book Listing for Six Patents Covering SDX and Confirmation of NCE Status KemPharm Added to
Toggle Summary KemPharm to Report Second Quarter 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021 , 4:30 p.m. ET CELEBRATION, Fla. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary